- Home
- HQL
as of 07-01-2026 3:51pm EST
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 585.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 127.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.84 - $20.20 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | 25.29 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare HQL vs Leading Stocks
See how HQL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HQL abrdn Life Sciences Investors Shares of Beneficial Interest - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.